Skip to content
DataLookout
Menu

AISLENCT07913919

Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Comparison of coronary artery 68Ga-DOTATATE maximum tissue-to-blood ratio (TBRmax) after 16 weeks of anifrolumab compared to baseline
Timeframe: Between baseline and following 16 weeks of anifrolumab therapy

Secondary (1)

Comparison of ascending aortic 68Ga-DOTATATE TBRmax after 16 weeks of anifrolumab compared to baseline

Arms and interventions

Anifrolumab armExperimental

In this single arm of the study patients with patients will undergoing PET/MRI before and after anifrolumab therapy

Diagnostic tests: 68-Gallium Dotatate

Drugs: Anifrolumab

Sites

1 site in 1 country

  • Addenbrookes HospitalCambridge, Cambridgeshire, United Kingdom